Living Lab Ventures, the corporate venture capital arm of Sinar Mas Land, has announced a strategic investment in INCREASE Laboratorium Indonesia, a clinical research and laboratory company headquartered in BSD City.
The move is poised to strengthen Indonesia’s capacity for globally standardised clinical trials and bolster the country’s emerging role in the biomedical innovation space.
The funding will support INCREASE’s operational expansion, global partnership development, and pursuit of international certifications, as the company aims to capitalise on growing regional demand for high-quality research services.
INCREASE delivers comprehensive, end-to-end clinical research solutions, spanning study design and regulatory affairs, through to clinical and bioanalytical testing. According to a press statement by Living Lab Ventures, its infrastructure, regulatory expertise, and experienced talent pool position it as a strong candidate to serve global pharmaceutical and biotech firms looking for a Southeast Asian research base.
“Indonesia has the potential to become a regional powerhouse in health and biomedicine,” said Bayu Seto, Partner at Living Lab Ventures. “We see INCREASE as a strategic platform that can catalyse the national clinical research ecosystem, attract global partners, and enhance the competitiveness of Indonesia’s healthcare sector.”
Also Read: Antler backs Malaysian AI startups M3TRIQ, NCSpeech driving innovation in biotech and fintech
As Southeast Asia’s healthcare landscape evolves, Indonesia’s clinical research sector is becoming increasingly vital. According to a report by 6Wresearch, the country’s Contract Research Organisation (CRO) market is projected to reach US$1 billion by 2030, growing at a CAGR of 10.6 per cent from 2024.
This surge is driven by the growing demand for efficient, scalable, and internationally compliant research infrastructure to support biopharmaceutical, medtech, and academic innovation.
The company’s current projects span clients from Indonesia, Singapore, Australia, and China.
INCREASE has already formed research partnerships with China’s Tsinghua University and Japan’s University of Osaka. These collaborations aim to facilitate technology transfer, joint R&D, and local talent training.
In pursuit of international validation, INCREASE is working toward certifications including those from the College of American Pathologists (CAP), ISO 9001:2015, ISO 17025:2017, and ISO 15189:2022.
For LLV and its parent, Sinar Mas Land, the investment aligns with a broader vision to transform BSD City into a global innovation district. “This investment reflects our belief that the convergence of science, technology, and infrastructure will be key to placing Indonesia on the global medical innovation map,” said Mulyawan Gani, CEO of Digital Business at Sinar Mas Land.
BSD City’s Biomedical Campus and D-HUB SEZ are central to this plan, offering a testbed for companies integrating IoT, AI, and other emerging technologies into healthcare solutions.
—
Image Credit: Living Lab Ventures
The post Living Lab Ventures backs INCREASE to strengthen Indonesia’s clinical research ecosystem appeared first on e27.